Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 2
2005 5
2006 4
2007 1
2008 3
2009 4
2010 8
2011 2
2012 9
2013 9
2014 9
2015 5
2016 10
2017 9
2018 10
2019 13
2020 13
2021 26
2022 20
2023 14
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Results by year

Filters applied: . Clear all
Page 1
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H. Kumagai S, et al. Among authors: nishikawa h. Cancer Cell. 2022 Feb 14;40(2):201-218.e9. doi: 10.1016/j.ccell.2022.01.001. Epub 2022 Jan 28. Cancer Cell. 2022. PMID: 35090594 Free article.
BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors.
Itahashi K, Irie T, Yuda J, Kumagai S, Tanegashima T, Lin YT, Watanabe S, Goto Y, Suzuki J, Aokage K, Tsuboi M, Minami Y, Ishii G, Ohe Y, Ise W, Kurosaki T, Suzuki Y, Koyama S, Nishikawa H. Itahashi K, et al. Among authors: nishikawa h. Sci Immunol. 2022 Oct 14;7(76):eabk0957. doi: 10.1126/sciimmunol.abk0957. Epub 2022 Oct 7. Sci Immunol. 2022. PMID: 36206353
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, Shibahara T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A, Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, Kawazu M, Ueno T, Yamazaki N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K, Nishikawa H. Kumagai S, et al. Among authors: nishikawa h. Nat Immunol. 2020 Nov;21(11):1346-1358. doi: 10.1038/s41590-020-0769-3. Epub 2020 Aug 31. Nat Immunol. 2020. PMID: 32868929
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.
Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, Morikawa H, Kawazoe A, Kinoshita T, Shitara K, Sakaguchi S, Nishikawa H. Kamada T, et al. Among authors: nishikawa h. Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008. doi: 10.1073/pnas.1822001116. Epub 2019 Apr 26. Proc Natl Acad Sci U S A. 2019. PMID: 31028147 Free PMC article.
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, Hirano N, Wakabayashi M, Nomura S, Sato A, Kuwata T, Togashi Y, Nishikawa H, Shitara K. Fukuoka S, et al. Among authors: nishikawa h. J Clin Oncol. 2020 Jun 20;38(18):2053-2061. doi: 10.1200/JCO.19.03296. Epub 2020 Apr 28. J Clin Oncol. 2020. PMID: 32343640 Clinical Trial.
176 results